FDA-tracked. Ozempic's side effect profile has expanded materially since approval: ileus added to the label in September 2023, NAION (sudden vision loss) flagged in 2025, and an active multidistrict lawsuit over severe gastroparesis as of 2026. Most effects are still temporary GI, but the serious ones are not, and they have grown in number.
Below: every documented side effect by severity, with clinical trial percentages, the 2024-2026 regulatory updates, and when to stop.
🔑 Key Takeaways
- Ozempic (semaglutide) has an FDA boxed warning for thyroid C-cell tumor risk, the most serious warning class the FDA issues
- Common GI side effects (nausea, diarrhea, constipation, vomiting) affect 10-44% of users depending on dose and peak at each dose increase, then fade within 2-8 weeks at a stable dose
- Serious risks include pancreatitis, gallbladder disease, kidney injury, severe gastroparesis, diabetic retinopathy worsening, and a newer 2025 label addition for sudden vision loss (NAION)
- Lawsuits: ongoing multidistrict litigation (MDL) centered on severe gastroparesis and vision loss claims; FDA continues post-marketing surveillance
- "Ozempic face," hair loss, and muscle loss are driven by rapid weight loss itself, not semaglutide directly, and are largely preventable with adequate protein, resistance training, and slower dose escalation
- Ozempic has a 1-week half-life and takes about 5 weeks to fully clear; side effects can continue during this clearance window
- When to stop and call a doctor: severe abdominal pain radiating to the back, yellowing eyes/skin, sudden vision changes, persistent vomiting, lump in the neck
This article documents every known Ozempic side effect: the common ones that resolve on their own, the serious ones that need medical attention, the long-term ones that depend on how you lose weight, and the newer 2024-2026 regulatory updates including the NAION vision-loss warning and the gastroparesis lawsuits. Each section covers what to watch for, what to do about it, and when to stop.
Ozempic FDA Boxed Warning
The most serious warning class the FDA issues.
Ozempic carries a boxed warning for thyroid C-cell tumor risk, including medullary thyroid carcinoma (MTC). Rodent studies showed dose-dependent tumors; human causation is not confirmed but cannot be ruled out. Ozempic is contraindicated in:
- Have a personal or family history of medullary thyroid carcinoma (MTC)
- Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Have a serious hypersensitivity reaction to semaglutide or any component of the formulation
Symptoms to watch for: a lump or swelling in the neck, hoarseness that does not resolve, persistent trouble swallowing, or shortness of breath. Report any of these to your doctor immediately.
Common Ozempic Side Effects
These are the dose-dependent GI effects that show up for most people, especially during dose escalation.
| Side effect | Frequency at 0.25-0.5mg | Frequency at 1-2mg | When it peaks |
|---|---|---|---|
| Nausea | 15-20% | 40-44% | First 1-2 weeks of each dose |
| Diarrhea | 8-12% | 20-30% | First 1-2 weeks of each dose |
| Vomiting | 5-9% | 15-24% | First 1-2 weeks of each dose |
| Constipation | 3-5% | 10-24% | Weeks 2-6 |
| Abdominal pain | 5-8% | 10-20% | First 2 weeks of each dose |
| Decreased appetite | Variable | Common | Persists throughout treatment |
| Fatigue | 5-8% | 10-15% | First month, improves over time |
| Dyspepsia (indigestion) | 3-5% | 8-10% | Ongoing; worse after fatty meals |
| Burping / acid reflux | 3-5% | 7-9% | Ongoing; worse at night |
| Headache | 2-4% | 5-8% | First 2 weeks |
| Dizziness | 2-4% | 4-7% | Early, often tied to dehydration |
GI effects peak 1-2 weeks after each dose increase and fade at a stable dose. By weeks 4-8 at steady state, most people are mildly symptomatic or asymptomatic.
Serious Ozempic Side Effects
Less common but require immediate medical attention when they occur.
Pancreatitis (Inflammation of the Pancreas)
Sudden, severe, persistent upper abdominal pain, often radiating to the back, is the classic presentation. It may come with vomiting, fever, or rapid heartbeat. Stop Ozempic and seek emergency care. Confirmed pancreatitis means Ozempic should usually not be restarted.
Gallbladder Disease (Cholelithiasis, Cholecystitis)
Rapid weight loss is itself a risk factor for gallstones, and Ozempic accelerates both. Symptoms: upper right abdominal pain, fever, nausea with vomiting, yellowing of the skin or eyes (jaundice), or clay-colored stools. Contact your doctor promptly; surgery may be needed for acute cases.
Acute Kidney Injury
Persistent nausea, vomiting, or diarrhea leads to dehydration, which can precipitate kidney injury, especially in older adults or those with pre-existing kidney disease. Symptoms: reduced urine output, swelling in legs or ankles, fatigue, shortness of breath. Stay hydrated aggressively; call your doctor if you cannot keep fluids down for 24+ hours.
Severe Gastroparesis (Stomach Paralysis)
Semaglutide slows stomach emptying as part of its mechanism. In some people this progresses to severe gastroparesis: persistent nausea, vomiting undigested food hours after eating, rapid fullness, weight loss beyond expected, and bloating. This is the adverse event driving the current Ozempic MDL lawsuits. Severe gastroparesis should not be treated as a transient side effect; stop the drug and see a GI specialist.
Diabetic Retinopathy Complications
In patients with pre-existing diabetic retinopathy, rapid improvement in blood glucose from any treatment, including Ozempic, can paradoxically worsen retinopathy in the short term. Symptoms: blurred vision, floaters, dark spots, or vision loss. A dilated eye exam before starting and at regular intervals is standard of care for diabetics.
NAION (Sudden Vision Loss), 2025 Label Update
In 2024-2025, research linked GLP-1 drugs including semaglutide to a higher risk of non-arteritic anterior ischemic optic neuropathy (NAION), a sudden, usually painless vision loss in one eye caused by blocked blood flow to the optic nerve. The FDA updated the Ozempic label to include this risk. Any sudden vision change, especially in one eye, needs same-day ophthalmology evaluation.
Ileus (Intestinal Paralysis)
In September 2023, the FDA added ileus to the Ozempic label after post-marketing reports. Symptoms: no bowel movements for several days, severe constipation with nausea and vomiting, swollen abdomen. Ileus is a medical emergency; stop the drug and go to the ER.
Severe Allergic Reaction (Anaphylaxis, Angioedema)
Rare but possible. Symptoms: swelling of the face, lips, tongue, or throat, difficulty breathing or swallowing, severe rash, fainting, or very rapid heartbeat. Call 911 or go to the ER immediately and stop Ozempic.
Hypoglycemia (Low Blood Sugar)
Ozempic alone rarely causes hypoglycemia. The risk rises significantly when Ozempic is combined with insulin or sulfonylureas like glipizide or glyburide. Symptoms: shakiness, sweating, confusion, rapid heartbeat, blurred vision. Your prescriber may need to reduce insulin or sulfonylurea doses when starting Ozempic.
The Ozempic Lawsuits: Gastroparesis and NAION Vision Loss
A multidistrict litigation (MDL) has consolidated cases against Novo Nordisk (Ozempic) and Eli Lilly (Mounjaro) alleging the manufacturers failed to adequately warn about severe gastroparesis and related GI complications. As of 2026, thousands of cases are pending in federal court. Separate complaints have emerged linking GLP-1 drugs to NAION-related vision loss.
Regulatory response:
- September 2023: FDA added ileus to the Ozempic prescribing information
- 2024: FDA issued updates addressing suicidal ideation after post-marketing reports; the agency's review ultimately did not conclude a causal link, but a warning remains in the prescribing literature
- 2025: FDA updated the Ozempic label with information about NAION vision loss risk
None of this makes Ozempic definitively unsafe for the average user. It does mean the risk profile at scale, especially for severe GI and rare ocular events, is more fully understood in 2026 than it was in 2018 when the drug was approved.
Long-Term Ozempic Side Effects
These show up after months or years of use, and most are consequences of rapid weight loss rather than semaglutide itself.
"Ozempic Face" and Loose Skin
Rapid loss of subcutaneous fat, especially in the face, can leave skin looking deflated, hollow-cheeked, and older. The same happens on the body (loose skin on arms, abdomen, thighs) when fat is lost faster than skin can retract. It is not semaglutide-specific. Any rapid weight loss does this. Prevention: slower dose escalation, adequate protein (1g per pound of target body weight), resistance training to maintain muscle underneath the skin, and collagen and peptide support (see GHK-Cu).
Hair Loss (Telogen Effluvium)
About 3-5% of Ozempic users report hair thinning, typically 2-4 months into treatment. The mechanism is telogen effluvium, where a stress trigger (rapid weight loss, nutritional changes) pushes hair follicles simultaneously into the shedding phase. It is usually reversible within 6-12 months after the trigger resolves. Prevention: adequate protein, iron, biotin, and zinc; avoid very-low-calorie intake.
Muscle Loss and Sarcopenia
Studies of GLP-1 weight loss programs show roughly 20-40% of lost weight can come from lean mass in the absence of deliberate muscle preservation. Over time this means reduced metabolic rate, weaker function, and higher risk of regaining fat as fat (not muscle) when you stop the drug. Resistance training 2-3x per week plus high protein intake (1.2-2g per kg target body weight) is essential.
Weight Regain After Stopping
The STEP 4 extension trial showed that stopping semaglutide led to regaining roughly two-thirds of the lost weight within 1 year. This is not a side effect in the pharmacological sense, but it is the most common practical consequence of stopping without a maintenance plan. Maintenance doses, lifestyle protocols, and sometimes alternate GLP-1 or precursor strategies are options to consider before discontinuing.
Bone Density Considerations
Large weight losses over 12+ months can modestly reduce bone mineral density. Weight-bearing exercise and adequate calcium, vitamin D, and protein intake mitigate this.
Mental Health Side Effects: Depression, Mood Changes, Suicidal Ideation
A specific sub-topic that has attracted regulatory attention.
In 2024, the FDA reviewed reports of suicidal ideation and depression in people using GLP-1 drugs. The agency's review did not establish a causal link, but scattered reports continue and the topic remains on the FDA watch list. Patient-reported experiences include:
- Low mood or blunted emotional response ("anhedonia")
- Reduced food-related pleasure and reward
- Anxiety spikes, especially during dose escalation
- Rare reports of suicidal thoughts
Any new or worsening mood changes, depression, or thoughts of self-harm while taking Ozempic require prompt clinical attention. Do not stop abruptly without medical input, but also do not ignore persistent mood changes.
Side Effects Specific to Women
Some effects are more commonly reported by women or affect women differently.
- Menstrual changes: Irregular cycles or changes in flow, particularly during significant weight loss
- Hair loss: Reported more frequently by women, likely reflecting baseline differences in reporting and hair sensitivity to weight changes
- Fertility shifts: Weight loss itself can restore ovulation in women with PCOS or polycystic ovary syndrome, leading to unexpected pregnancies; reliable contraception is essential while taking Ozempic because pregnancy is not advised
- Ozempic face: More noticeable cosmetically in women, who tend to have thinner facial fat pads
- Breastfeeding: Not recommended; semaglutide transfer into breast milk has not been fully characterized
Ozempic Pregnancy and Breastfeeding Safety
Ozempic is not recommended during pregnancy.
In animal studies, semaglutide caused fetal death, structural abnormalities, and pregnancy losses. Human pregnancy data is limited. The FDA-approved prescribing information recommends stopping Ozempic at least 2 months before trying to conceive, to allow the drug to fully clear the body (5-week half-life-based washout).
If pregnancy is confirmed while on Ozempic, most clinicians will recommend stopping immediately and discussing glucose management alternatives with an OB/GYN or endocrinologist.
Drug and Alcohol Interactions
- Insulin and sulfonylureas: Significantly increased risk of hypoglycemia; dose adjustments needed
- Oral medications: Slowed stomach emptying can delay absorption of other oral drugs; especially relevant for time-sensitive meds like antibiotics, thyroid medication, or oral contraceptives (for the last of these, consider backup contraception)
- Warfarin and other anticoagulants: Changes in absorption may affect INR; monitor more closely during dose adjustments
- Alcohol: Increases risk of hypoglycemia, pancreatitis, and nausea; heavy drinking should be avoided entirely on Ozempic
- NSAIDs: In combination with dehydration from GI effects, NSAIDs can increase kidney injury risk
[Image #1]
Who Should Not Take Ozempic
Ozempic is contraindicated or requires particular caution in:
- Personal or family history of medullary thyroid carcinoma (MTC), contraindicated
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), contraindicated
- Severe gastroparesis, not recommended
- History of pancreatitis, use with caution or avoid
- Type 1 diabetes, not approved, not a substitute for insulin
- Pregnancy or planning pregnancy within 2 months, discontinue
- Breastfeeding, not recommended
- Severe kidney disease without specialist guidance
- Severe hypersensitivity to semaglutide or inactive ingredients, contraindicated
- Children under 12 (Wegovy is approved for adolescents 12+, Ozempic is not)
How to Manage Ozempic Side Effects
GI Side Effects (Nausea, Diarrhea, Constipation)
- Inject at night: Sleep through the nausea peak, single most effective mitigation
- Eat smaller, lower-fat meals: Large or fatty meals overwhelm the slowed stomach
- Avoid fried, spicy, or very sweet foods: These trigger nausea most reliably
- Hydrate aggressively: Electrolyte-containing fluids help prevent dehydration-driven kidney issues
- Add fiber for constipation: Psyllium or magnesium citrate; make sure fluid intake is high
- Slow the escalation: Stay at the current dose longer rather than moving up on schedule if side effects are severe
- OTC options: Ginger for nausea, loperamide short-term for diarrhea, stool softeners for constipation, always check with your pharmacist first
Fatigue
Usually reflects reduced caloric intake, dehydration, or electrolyte shifts. Ensure adequate protein (at least 0.7g per pound body weight), electrolytes, and sleep.
Injection Site Reactions
Rotate injection sites between abdomen, thigh, and upper arm. Let the pen come to room temperature 15-30 minutes before injecting to reduce sting.
Dose Escalation Strategy
The standard schedule is 0.25mg → 0.5mg → 1mg → 2mg in 4-week intervals. If side effects are severe at any step, staying at the previous dose for another 4 weeks before escalating significantly reduces problems for most people.
Real-World Side Effect Patterns: What Users Actually Report vs Trial Data
Clinical trial percentages and post-marketing reports tell different stories.
SUSTAIN and STEP trials measured nausea at 15-44%, diarrhea at 8-30%, and pancreatitis under 0.5%. Those numbers describe controlled populations in 52-104 week protocols. What gets reported to the FDA MedWatch system and aggregated in community discussions reveals patterns trials miss:
| Effect | Trial rate (labeled) | Real-world pattern |
|---|---|---|
| Nausea at dose escalation | 15-44% | Nearly universal first week of each new dose; most report it severe enough to skip meals for 2-3 days |
| "Food noise" reduction | Not tracked in trials | The most consistently reported subjective effect, often within 48-72 hours of first dose |
| Sulfur burps | Buried under "dyspepsia" in labels | One of the most-searched Ozempic symptoms; highly characteristic, often intense |
| Alcohol tolerance change | Not in FDA label | Majority of users report dramatically reduced alcohol tolerance; 1 drink feels like 3 |
| Cravings for specific foods | Not tracked | Aversion to fatty, greasy, or very sweet foods is commonly reported |
| Constipation severity | 3-24% | Real-world duration often longer than trial-reported; many users need ongoing fiber or stool softener |
| Post-dose fatigue crash | 8-15% "fatigue" | Day 1-2 after each dose commonly described as "Ozempic flu"; not a formal diagnosis |
| Gastroparesis (severe) | Post-marketing signal | FDA ileus label addition (September 2023) was driven by real-world reports, not initial trial data; gastroparesis MDL reflects the same gap |
What this means practically: the FDA-approved label captures the statistical picture. Patient experience often maps to the intensity and specificity of effects rather than their frequency. Talk to your prescriber about what you are actually experiencing, not just whether it matches the label's list.
When to Call Your Doctor or Go to the ER
Call your doctor promptly for:
- Persistent nausea or vomiting lasting more than 48 hours
- Severe constipation with no bowel movement for 5+ days
- Ongoing abdominal pain that does not resolve between meals
- Hair loss that is progressive beyond 4 months
- New or worsening mood changes, depression, or anxiety
- Rapid weight loss (more than 2-3 lbs per week for extended periods)
Go to the ER or call 911 for:
- Severe, sudden upper abdominal pain radiating to the back (possible pancreatitis)
- Yellowing of the eyes or skin (possible gallbladder emergency)
- Sudden vision loss, especially in one eye (possible NAION)
- Vomiting blood or passing black tarry stools
- No bowel movement, severe bloating, with nausea and vomiting (possible ileus)
- Swelling of the face, lips, tongue, or throat, or trouble breathing (possible anaphylaxis)
- Chest pain, severe shortness of breath, or signs of stroke
- Suicidal thoughts or self-harm urges
What Happens When You Stop Ozempic
Appetite suppression fades over 4-6 weeks as the drug clears, food noise returns, and most people regain weight unless lifestyle changes are firmly established.
- Clearance timeline: Semaglutide has a half-life of roughly 1 week; full clearance is ~5 weeks after the last injection
- Weight regain: STEP 4 trial data showed about two-thirds of lost weight returns within 1 year of stopping
- Rebound hunger: Some users report increased hunger beyond their pre-Ozempic baseline for several weeks
- GI normalization: Stomach emptying rates return to normal; food tolerance improves
- Diabetic retinopathy progression: Can continue even after Ozempic is cleared; eye monitoring should continue
- Maintenance options: Lower-dose Ozempic, transition to alternative GLP-1, or structured nutrition/training programs are the main paths
Ozempic vs Wegovy Side Effects: Same Drug, Different Dose
Ozempic and Wegovy are both semaglutide. The side effect profile is identical in kind, but differs in frequency because Wegovy is dosed higher.
| Property | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Approved for | Type 2 diabetes | Chronic weight management |
| Dose range | 0.25-2mg weekly | 0.25-2.4mg weekly |
| Nausea (max dose) | ~40-44% | ~44-48% |
| Diarrhea (max dose) | ~20-30% | ~30-35% |
| Discontinuation rate | ~7% | ~7-10% |
| Boxed warning | Thyroid C-cell tumors | Thyroid C-cell tumors |
In practice: if Ozempic causes you problems, Wegovy probably will too, and likely worse. Mounjaro (tirzepatide) has a slightly different side-effect profile at comparable weight-loss magnitudes and is sometimes better tolerated. See our tirzepatide side effects guide and Tirzepatide vs Ozempic comparison.
How Long Each Side Effect Lasts
| Side effect | Typical duration | Resolution pattern |
|---|---|---|
| Nausea | 1-2 weeks per dose step | Resolves at stable dose |
| Diarrhea | 1-2 weeks per dose step | Resolves at stable dose |
| Constipation | Can persist throughout | Manageable with fiber and fluids |
| Fatigue | 2-4 weeks | Resolves with caloric and protein adequacy |
| Hair loss | 3-6 months shedding, 6-12 months regrowth | Usually reversible |
| Ozempic face / loose skin | Persists until weight and muscle rebuild | Partially reversible |
| Pancreatitis | Days to weeks (acute) | Resolves with treatment; may recur |
| Gallbladder issues | Can be persistent or require surgery | Depends on severity |
| Retinopathy changes | Progressive or stable | Requires ophthalmology follow-up |
| NAION | Usually permanent vision loss | Irreversible in most cases |
References and Official Resources
- FDA prescribing information for Ozempic (semaglutide): accessdata.fda.gov Ozempic label, current as of 2025 update
- FDA MedWatch adverse event reporting: 1-800-FDA-1088 or FDA.gov/MedWatch
- National Library of Medicine: SUSTAIN-1 through SUSTAIN-10 trials (semaglutide clinical trial program)
- STEP 1-5 trials (semaglutide weight management program)
- FDA boxed warning reference: Ozempic Prescribing Information, Thyroid C-Cell Tumor section
- FDA ileus addition: September 2023 label update
- FDA NAION addition: 2025 label update